2006
DOI: 10.1089/rej.2006.9.378
|View full text |Cite
|
Sign up to set email alerts
|

Targeting Telomerase

Abstract: Given the constitutive expression of telomerase in the majority of human tumors, telomerase inhibition is an attractive, broad-spectrum therapeutic target for cancer treatment. Therapeutic strategies for inhibiting telomerase activity have included both targeting components of telomerase (the protein component, TERT, or the RNA component, TERC) or by directly targeting telomere DNA structures. Recently a combination telomerase inhibition therapy has been studied also. The TERT promoter has been used to selecti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2008
2008
2019
2019

Publication Types

Select...
6
4

Relationship

1
9

Authors

Journals

citations
Cited by 19 publications
(5 citation statements)
references
References 73 publications
0
5
0
Order By: Relevance
“…A study by Reddel and colleagues [101] identifies a correlation between patient age and ALT activation, which is seen mostly in young individuals [101]. Furthermore, it has also been discussed that treatment of telomerase-positive tumors with telomerase inhibitors may select for cells which activate ALT [104, 105]. Thus, fully understanding the role of BLM and its modification on APB formation and telomere recombination could potentially provide novel therapeutic targets, particularly because significant progress has been made in developing small molecule inhibitors of BLM [106].…”
Section: Discussionmentioning
confidence: 99%
“…A study by Reddel and colleagues [101] identifies a correlation between patient age and ALT activation, which is seen mostly in young individuals [101]. Furthermore, it has also been discussed that treatment of telomerase-positive tumors with telomerase inhibitors may select for cells which activate ALT [104, 105]. Thus, fully understanding the role of BLM and its modification on APB formation and telomere recombination could potentially provide novel therapeutic targets, particularly because significant progress has been made in developing small molecule inhibitors of BLM [106].…”
Section: Discussionmentioning
confidence: 99%
“…Cells of the germ line, stem cells and some other normal diploid cells contain an enzyme called telomerase that replaces telomer DNA lost during cell division. The possibility of reversing cellular senescence by switching on a copy of the gene encoding the telomerase catalytic subunit into normal cells, thus turning on telomerase activity has been considered [24][25][26][27][28][29][30][31][32][33][34][35]. This strategy may also increase the risk that cells become immortalized.…”
Section: Cellular Senescence and Telomeresmentioning
confidence: 99%
“…Never-theless, anti-telomerase therapies are obviously of no value in telomerase non-expressing tumours, not to mention potential toxicity due to off-target effects. Furthermore, anti-telomerase treatment can always drive to selection for resistant cells that may activate an ALT mechanism [167]. These data render ALT an attractive target for anti-tumour therapies based on a personalized treatment approach.…”
Section: Alt-mediated Telomere Elongationmentioning
confidence: 99%